Medicinova Inc (MNOV) Stock
Fundamentals
Recent news
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MNOV
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
MNOVTechnicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MNOVMediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
MNOVAbout Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, CEO & Chairman | 1950 |
| Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Senior VP, Chief Medical Officer & Director | 1966 |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer | 1965 |
| Mr. Jason J. Kruger CPA | CFO & Principal Financial Officer | 1978 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.3 | -12.7 | -4.9 | -11.6 | ||||||||
| 2022 | -12.9 | -5.9 | +13.6 | +2.7 | -7.3 | +5.0 | -6.5 | -8.6 | +0.5 | -8.1 | +26.3 | -22.1 |
| 2023 | +10.1 | -8.3 | -1.4 | +0.5 | +2.9 | +4.5 | +3.9 | +4.3 | -12.2 | -5.9 | -3.7 | -15.7 |
| 2024 | -14.5 | -6.2 | +7.4 | -12.2 | +5.4 | -2.0 | -0.7 | |||||
| 2026 | +27.7 |
